Stuart Naylor, the Chief Scientific Officer, Ophthalmology of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 27,659 shares of ordinary shares on July 7, 2026, according to an SEC Form 4 filing.
Transaction summary
Key questions
What were the execution details regarding the price of the sold shares?
The transaction was carried out in multiple tranches with prices ranging from $13.36 to $15.33, resulting in a weighted average execution price of $14.80 per share.How does this sale fit into the insider’s broader investment strategy?
The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025, which allows insiders to diversify their portfolios through pre-scheduled transactions.What is the scale of the remaining equity position held by the insider?
Following this 4% reduction in direct holdings, Stuart Naylor retains 641,000 shares of MeiraGTx, which had a total market value of $9.39 million based on the July 7, 2026 close of $14.66.What has been the recent market context for MeiraGTx stock?
At the time of the transaction, MeiraGTx had realized a one-year return of 89%, with the stock priced at $13.89 as of the July 6, 2026 market close.
Company Overview
Company Snapshot
MeiraGTx is a clinical-stage gene therapy company developing therapeutic solutions for serious illnesses, including inherited ocular diseases, xerostomia following radiation treatment for head and neck cancers, and various degenerative and neurodegenerative disorders.
The company generates revenue through its clinical-stage gene therapy programs and development partnerships, with a business model focused on advancing proprietary gene therapy candidates through clinical development toward commercialization.
MeiraGTx targets patients suffering from serious genetic and degenerative conditions, with primary focus on ophthalmology, oncology supportive care, and neurodegenerative disease markets.
MeiraGTx Holdings plc operates as a clinical-stage biotechnology company with a market capitalization of $1.4 billion. The company has demonstrated significant momentum, with its stock appreciating 89% over the past year, reflecting investor confidence in its gene therapy pipeline. MeiraGTx’s competitive positioning centers on its proprietary gene therapy platform targeting high-unmet-need indications across multiple therapeutic areas, though the company remains in clinical development stages with negative net income reflecting typical early-stage biotech investment patterns.
